Department of Neurology, Heinrich-Heine-University Düsseldorf, Germany.
Clin Immunol. 2012 Jan;142(1):68-75. doi: 10.1016/j.clim.2011.05.009. Epub 2011 Jun 1.
There is an unmet need for more potent and convenient drugs in the treatment of patients diagnosed with multiple sclerosis (MS). Among five currently investigated oral drugs with an ongoing or completed phase III program, promising efficacy data for oral cladribine have recently been published. However, benefits need to be weighed against potential risks to define the role of this compound within current treatment regimens. Here we review present data on efficacy of oral cladribine and discuss known and anticipated risks of this drug.
在治疗多发性硬化症（MS）患者方面，存在对更有效和更方便的药物的未满足需求。在目前正在进行或已完成 III 期研究的五种口服药物中，最近公布了口服克拉屈滨的有前途的疗效数据。然而，需要权衡利弊，以确定该化合物在当前治疗方案中的作用。本文回顾了口服克拉屈滨的疗效数据，并讨论了该药物的已知和预期风险。
